Growth momentum BlueWind Medical is preparing a limited U.S. launch of Revi Extend in Q4 2026 following a $47.8 million financing round in May 2026, signaling potential rapid market entry and expanded commercialization opportunities for neuromodulation devices.

Strategic product The Revi System is a patient-centric, implantable tibial neuromodulation technology for urgency urinary incontinence, offering a configurable therapy approach that can be leveraged in conversations with clinicians seeking minimally invasive outpatient solutions.

Clinical validation OASIS study three-year results were presented, reinforcing evidence around efficacy and safety which can be used to support clinical adoption discussions with urology and pelvic medicine specialists.

Funding health With total funding at around $112M, BlueWind has financial backing to support sales and field activities, enabling local/regional deployments, training, and clinic adoption initiatives.

Market positioning As a relatively small but fast-growing player in implantable neuromodulation for UUI, BlueWind presents an attractive alternative for hospitals and clinics seeking innovative, patient-friendly devices with potential partnerships beyond large incumbents.